CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

OPTIMAL USE OF LIPID-LOWERING THERAPY AFTER ACUTE CORONARY SYNDROMES: A Position Paper endorsed by the International Lipid Expert Panel (ILEP) Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial Coronary CT Angiography and 5-Year Risk of Myocardial Infarction

Clinical Trial14 Oct 2020

JOURNAL:Circulation. Article Link

Effect of Pre-Hospital Crushed Prasugrel Tablets in Patients with STEMI Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial

GJ Vlachojannis , JM Wilschut , RF Vogel et al. Keywords: pre-hospital crushed prasugrel tablet vs. integral prasugrel tablet; oral platelet P2Y12 inhibiton

Full Text PDF